About Uniqsis
Uniqsis is a Healthcare company based in United Kingdom founded in 2007, and was acquired by Asynt in September 2024. Provider of flow chemistry reactors and systems for continuous flow reactions in the field of chemistry. It operates in the Healthcare and Chemicals & Materials sectors. Uniqsis has raised $299.35 thousand across 3 funding rounds from investors including Asynt. Its chief executive, as recorded, is Martyn Fordham. Uniqsis offers products and services including FlowSyn System and Photoreactors. Its focus areas include Chemicals and Materials and Chemical Equipment Manufacturers. Its legal entity is Uniqsis Ltd.
Company details
It is a flow chemistry specialist based in Cambridge, UK, and Boston, MA, USA. They supply FlowSyn continuous flow reactors, also known as plug flow reactors, for various chemistry applications. They offer reactor modules, such as Polar Bear Plus GSM and PhotoSyn, as well as FlowLab Systems and FlowSyn Maxi. Uniqsis focuses on improving the reproducibility and efficiency of flow chemistry reactions.
Products & Services of Uniqsis
Uniqsis offers a comprehensive portfolio of products and services, including FlowSyn System and Photoreactors.
A modular system for flow chemistry reactions is provided to support chemical processes in laboratories.
Various photoreactors are supplied for photochemical applications, including high-power systems for reaction sequences.
Apps and channels of Uniqsis
its YouTube channel Asynt has 6.15K subscribers and 30 videos.
Videos from Uniqsis
The most watched videos on Uniqsis's YouTube channel, Asynt (6.15K subscribers). Click a video to play it here.
More on Asynt.
Funding Insights of Uniqsis
Uniqsis has successfully raised a total of $299.35K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $21.95 thousand completed in April 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $299,350
- Total Rounds 3
- Last Round Seed — $21,946
- First Round $186,991
(Mar 2007)
All 3 funding rounds of Uniqsis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2010 | $21,946 | Seed | – | – | – |
| Feb 2008 | $90,413 | Seed | – | – | – |
| Mar 2007 | $186,991 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Uniqsis
Uniqsis has secured backing from 1 investor. Prominent investors backing the company include Asynt.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global supplier of chemistry technologies and laboratory tools for research. | 2003 | asynt.com | Cambridge, United Kingdom |
Investor details for Uniqsis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Uniqsis
1 people are tracked at Uniqsis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Martyn Fordham | CEO | Leadership |
Complete people profiles for Uniqsis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Uniqsis
4 dated milestones of Uniqsis across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Uniqsis is founded.
- Funding First funding round of $187K.
- Funding Latest funding round, Seed, of $22K.
- Exit Acquired by Asynt.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Uniqsis (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Uniqsis
Uniqsis was founded in 2007.
Uniqsis is headquartered in United Kingdom. It is registered at Cambridgeshire, United Kingdom.
Martyn Fordham is the CEO of Uniqsis, as recorded in our data.
Uniqsis is a funded company, having raised a total of $299.35K across 3 funding rounds to date. The company's 1st funding round was a Seed of $186.99K, raised on Mar 2007.
It is a flow chemistry specialist based in Cambridge, UK, and Boston, MA, USA. They supply FlowSyn continuous flow reactors, also known as plug flow reactors, for various chemistry applications. They offer reactor modules, such as Polar Bear Plus GSM and PhotoSyn, as well as FlowLab Systems and FlowSyn Maxi. Uniqsis focuses on improving the reproducibility and efficiency of flow chemistry reactions.
Uniqsis offers FlowSyn System and Photoreactors.
Uniqsis has 1 investor. Key investors include Asynt.
Uniqsis operates through Uniqsis Ltd.
Yes. Uniqsis was acquired by Asynt in September 2024.